Researcher Spotlight – Benita Katzenellenbogen, PhD

Most breast cancers require estrogen to grow. While 5-year prognosis of early stage, estrogen-driven breast cancers (called ER-positive) is very good, late recurrence and resistance to anti-estrogen therapies reduce overall survival for many patients. Dr. Katzenellenbogen is developing alternative therapeutic approaches to benefit women whose tumors no longer respond to anti-estrogen therapy.  For complete details, please visit